FDA Accepts sNDA for Aminolevulinic Acid Gel in Superficial Basal Cell Carcinoma
Mar 09, 2026
The FDA has accepted a supplemental new drug application for aminolevulinic acid hydrochloride plus red light therapy for superficial basal cell carcinoma, with a decision date set for September 28, 2026.